Efficacy of lanreotide Autogel�administered every 4?8�weeks in patients with acromegaly previously responsive to lanreotide microparticles 30�mg: a phase III trial-Reference-Cited by-同舟云学术

Efficacy of lanreotide Autogel�administered every 4?8�weeks in patients with acromegaly previously responsive to lanreotide microparticles 30�mg: a phase III trial

Published:2006-09 Issue:3 Volume:65 Page:320-326
ISSN:0300-0664
Container-title:Clinical Endocrinology
language:en
Short-container-title:Clin Endocrinol

Author:

Lucas T.,Astorga R.,

Publisher

Wiley

Subject

Endocrinology, Diabetes and Metabolism,Endocrinology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2265.2006.02595.x/fullpdf

Reference32 articles.

1. Plasma Growth Hormone Responses to Somatostatin (SRIH) and SRIH Receptors in Pituitary Adenomas in Acromegalic Patients*

2. The Growth Hormone Responses to Octreotide in Acromegaly Correlate with Adenoma Somatostatin Receptor Status

3. Long-Term Safety and Efficacy of Depot Long-Acting Somatostatin Analogs for the Treatment of Acromegaly

4. Primary medical therapy for acromegaly

5. Preoperative lanreotide treatment for GH-secreting pituitary adenomas: effect on tumour volume and predictive factors of significant tumour shrinkage

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A systematic literature review to evaluate extended dosing intervals in the pharmacological management of acromegaly;Pituitary;2022-11-29

2. Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly;Endocrine;2020-07-28

3. ACROSTART: A retrospective study of the time to achieve hormonal control with lanreotide Autogel treatment in Spanish patients with acromegaly;Endocrinología, Diabetes y Nutrición;2019-05

4. ACROSTART: A retrospective study of the time to achieve hormonal control with lanreotide Autogel treatment in Spanish patients with acromegaly;Endocrinología, Diabetes y Nutrición (English ed.);2019-05

5. Somatostatin analogs, cabergoline and pegvisomant: comparing the efficacy of medical treatment for acromegaly;Expert Review of Endocrinology & Metabolism;2016-09-07